20/20 Gene Systems CEO Jonathan Cohen Explains How His Company is Successfully Using Equity Crowdfunding

Regulation A+ and Reg.CF crowdfunding spans just about any industry out there, and medical is BIG! While many struggle, 20/20 Gene Systems is a great example of how to do crowdfunding the right way. Listen and learn first-hand from company CEO Jonathan Cohen about what his company exactly does, its goals, strategies, and how investors can get involved. Whether you’re an established company or pre-revenue, listening to this podcast and understanding the insights provided by Mr. Cohen will give you the confidence to move forward with your crowdfunding efforts. With a current raise of over $4.4 million dollars on the SeedInvest crowdfunding portal, the success of 2020 Gene Systems provides more proof that Regulation A+ / Reg.CF crowdfunding isn’t just good for entrepreneurs and issuers, but also good for investors as well.

Listen to “20/20 Gene Systems CEO Jonathan Cohen Explains How His Company is Successfully Using Equity Crowdfunding” on Spreaker.

The crowdfunding success of 20/20 can be yours as well if you get started today and align yourself with knowledgeable professionals to guide you along the way! As mentioned on the podcast, for their worldwide vision of detection and precision medicine in the battle against cancer, 20/20 Gene Systems has introduced OneTEST, a screening test which identifies cancer risks using tumor antigen markers enhanced with 20/20’s proprietary algorithms that incorporate the patient’s individual risk factors to give a more accurate cancer risk profile. Cancer is the second leading cause of death in the world. However, many tumors are not lethal if detected early enough to be surgically removed before they spread. 20/20 Gene Systems’ “OneTest” flagship product is now being made available at participating Urgent / Primary Care Centers throughout the U.S. Interested consumers who learn about the product from general advertising can schedule an appointment or visit these walk-in clinics, usually located in shopping centers, on evenings or weekends, engage with informed healthcare practitioners, and provide a blood specimens which are sent to 20/20’s clinical laboratory for processing. Get more information at their website here.

ABOUT OUR GUEST: Jonathan Cohen

Jonathan CohenJonathan Cohen, Founder, President, and CEO: Under Mr. Cohen’s leadership, 20/20 Gene Systems has brought in approximately $7.5 million in grant funding and launched two successful products, a kit for suspicious powders used by hundreds of emergency responder organizations worldwide and a blood test for the early detection of lung cancer.

He is the co-inventor of an AI approach for improving tumor biomarker accuracy that is covered in a pending PCT International Patent Application.

As 20/20’s CEO, Mr. Cohen forged strategic alliances with Fortune 500 companies such as Johnson & Johnson, Eastman Kodak, Abbott Diagnostics, Smiths Detection, and Ping An Ventures, the investment arm of the largest insurance company in China. Active in public policy initiatives on behalf of the biotechnology industry, Mr. Cohen conceived of and helped bring about the passage of the Maryland Biotechnology Investment Tax Credit. Mr. Cohen is a founding director of the Small Biotechnology Business Coalition. Before founding 20/20, Mr. Cohen was patent and general counsel for two publicly traded companies: Ventana Medical Systems Inc. (acquired by Roche diagnostics in 2008 for $3.4 billioni) and Oncor Inc. Mr. Cohen is a registered patent attorney with more than 18 years of experience in biotechnology patents and licensing matters. He has a Master of Science in Biotechnology from Johns Hopkins University and a law degree from the American University.

20/20 GeneSystems, Inc. is a Rockville, MD based company focused on reducing cancer mortality worldwide. 20/20’s mission is to help “bend the curve” of cancer mortality around the world through early detection and precision medicine. It has pioneered a novel approach called “20/20 Hindsight” of continuous machine learning using large patient data sets of biomarker values with clinical factors such as age, gender, and smoking history to improve the accuracy of the most widely used cancer biomarkers. Their flagship product, “OneTEST” – a new multi cancer test which can help detect over 6 types of cancer, with up to 90% accuracy, using a standard blood test – is now available in a number of clinical centers.

All information provided is for informational purposes only. This information is not intended as legal or investment advice for anyone to make an investment in any one particular company and is not intended for any companies to rely on this information to form an opinion to go public or not to go public or to do any type of offering of securities. You must check with a securities attorney to find out if an offering is for you, or if you are going to be in the business of selling any type of securities, you need to make sure you are following your state and federal legislative law so you do not get into any troubles. Do not use the opinions as stated on this show as any way to form an opinion as what is wrong or right or what could be done for your business or as an investor.